AN2 Therapeutics Inc./$ANTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Ticker
$ANTX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
22
ISIN
US0373261058
Website
ANTX Metrics
BasicAdvanced
$32M
-
-$1.52
-0.08
-
Price and volume
Market cap
$32M
Beta
-0.08
52-week high
$1.55
52-week low
$1.01
Average daily volume
333K
Financial strength
Current ratio
8.68
Quick ratio
8.405
Profitability
Management effectiveness
Return on assets (TTM)
-29.49%
Return on equity (TTM)
-49.32%
Valuation
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.742
Free cash flow yield (TTM)
-134.69%
Free cash flow per share (TTM)
-141.43%
Growth
Earnings per share change (TTM)
-39.82%
3-year earnings per share growth (CAGR)
-50.49%
ANTX News
AllArticlesVideos
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
Business Wire·5 days ago
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AN2 Therapeutics Inc. stock?
AN2 Therapeutics Inc. (ANTX) has a market cap of $32M as of July 05, 2025.
What is the P/E ratio for AN2 Therapeutics Inc. stock?
The price to earnings (P/E) ratio for AN2 Therapeutics Inc. (ANTX) stock is 0 as of July 05, 2025.
Does AN2 Therapeutics Inc. stock pay dividends?
No, AN2 Therapeutics Inc. (ANTX) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next AN2 Therapeutics Inc. dividend payment date?
AN2 Therapeutics Inc. (ANTX) stock does not pay dividends to its shareholders.
What is the beta indicator for AN2 Therapeutics Inc.?
AN2 Therapeutics Inc. (ANTX) has a beta rating of -0.08. This means that it has an inverse relation to market volatility.